In this article, I will attempt the somewhat daunting task of delineating current theories on the sequence of events that lead to Parkinson's disease. Any review of this nature must border on a discussion of the cause of the disease which, of course, remains unknown. Nonetheless, with our increasing knowledge about the nigrostriatal system, both in normality and disease, it seems that the time is right to put some of the pieces together in an attempt to narrow down the factors that might eventually lead to what we know as Parkinson's disease.
Aging
One cannot discuss the cause of Parkinson's disease without also taking into consideration the importance of aging. This is true for two reasons. First, Parkinson's disease is primarily a disease ofolder individuals; it is rare before the age of 40 years, and the incidence rate increases at least until the sixth or seventh decade of life. Thus, aging itself appears to be a key susceptibility factor for Parkinson's disease. Secondly, the major substrate upon which the disease appears to act, the dopaminergic nigrostriatal system, is itself affected by the aging process. Carlsson and Winblad' were the first to point out that there appears to be a gradual decline in striatal dopamine concentrations throughout life, progressing at a rate of approximately 5 to 8% per decade. Thus, within the Parkinsonian nigrostriatal system, there is an unavoidable mingling of the decline that occurs normally with aging, and loss of function that occurs as part of the disease process due to Parkinson's disease. This brings us to the first in a series of dilemmas that are encountered when attempting to sort out which factors are important in Parkinson's disease and which are not.
First, the reason for the normally-occurring agerelated decline in striatal dopamine, which may or may not reflect a loss of dopaminergic neurons in the substantia nigra, is not known. One possibility is that this process is genetically programmed. If this were the case, it would represent a true aging phenomenon, as aging itself is probably under genetic control. Interestingly, the catecholaminergic nuclei of the brainstem were at one time suggested as possible "pacemakers"2 for the aging process. If the process is indeed preprogrammed, then it would be of great interest to know exactly how the decline is orchestrated.
A second possibility is that this system, through some intrinsic defect, is particularly prone to injury. The two most commonly cited factors that might lead to excessive wear and tear on the nigrostriatal dopaminergic system are free radical production and the accumulation of neuromelanin. The free radical hypothesis, of course, has its origin in the fact that striatal dopamine concentrations are particularly high compared with other areas of brain; for each mole of dopamine that is oxidised by monoamine oxidase (MAO), a mole of hydrogen peroxide is generated. This excess of hydrogen peroxide, and possibly other oxyradicals, could be damaging to neurons. Although there are a number ofenzymes that protect against free radicals, including superoxide dismutase and glutathione peroxidase, it does seem possible that with time these systems might fail or at least prove inadequate to completely prevent long-term damage from free radical formation. Auto-oxidation of dopamine also results in the formation of quinones, which themselves may be toxic,3 probably through a mechanism of covalent binding. disease and what is normal aging without knowing the cause ofthe aging phenomenon), perhaps research efforts should focus more on the cause of the normal age-related decline, thus allowing us to put an essential piece of the puzzle in place before we pursue our studies of Parkinson's disease further. Only then might we be able to address the key question of whether or not the process responsible for nigrostriatal degeneration during aging is the same or differentfrom that which causes Parkinson's disease. It should also be noted that, while this discussion is focused primarily Langston on dopamine depletion in the striatum, it is still unclear ifthe decline in striatal dopamine reflects a loss of nigral neurons, or simply a decline in cellular function; this important question also warrants further study.
Aging plus an environmental insult
An alternative explanation to an acceleration of an age-related decline in the nigrostriatal system is the hypothesis put forth by Calne and Langston9 several years ago. This hypothesis proposes that the substantia nigra is damaged as the result of an environmental insult at some point early in life, resulting in a partial loss of dopaminergic neurons; the insult would remain asymptomatic unless it was adequate to produce greater than the 80% depletion of striatal dopamine required to induce clinical evidence of Parkinsonism. In this situation, if the normal agerelated decline in striatal dopamine continued unabated, the 80% threshold might be reached many years later.
This hypothesis predicts that the rate of cell loss in Parkinson's disease and in normal aging should be the same; indeed, one could argue it might be even less in Parkinson's disease, as there are fewer cells remaining to undergo degeneration. While gliosis itself is not a good monitor of a rate ofdisease progression, one can refine this question by studying microglia. A proliferation of microglia generally indicates an active process. This is particularly true if one looks for microglial nodules, which usually indicate neuronophagia. Recently, McGeer and colleagues'0 have studied this question using quantitative techniques. By staining microglia using immunohistochemical techniques for HLA-DR, these investigators showed that a number of positive cells in Parkinsonian brains were 196 ± 66 per 5 high-power fields, as opposed to 16 ± 12 in agematched controls. If the counts were limited to neuronophagias, the numbers were still at least six times higher in patients with Parkinson's disease. Thus, it appeared that the rate of neuronal cell degeneration was considerably higher in Parkinsonian patients than could be accounted for on the basis of normal age-related neuronal degeneration alone. These results argue against the hypothesis that normal aging alone can account for the appearance of Parkinson's disease many years after a partial insult to the substantia nigra.
However, there is an elaboration of this hypothesis that resolves this problem. After partial cell loss of nigral neurons, one might expect increased dopamine turnover in the remaining neurons as a compensatory mechanism. This, of course, would result in increased oxidative stress which, in turn, might lead to additional cell loss. Thus, a vicious cycle could be set in Current theories on the cause ofParkinson's disease motion, accelerating the process of neuronal loss. Thus, after an environmental insult, rather than an age-related decline that parallels that which is seen with normal aging, there could be an acceleration of this process, thereby explaining the data of McGeer et al. '" Hypotheses are not very useful if they cannot be tested. For this reason, the DATATOP study" which involves the testing of both deprenyl and alpha-tocopherol in early, untreated Parkinson's disease, is particularly important. This double-blind, placebocontrolled trial should allow us to determine for the first time whether therapeutic intervention with a free radical scavenger (in this case alpha-tocopherol) might actually retard the process ofneuronal degeneration in Parkinson's disease. A positive result would support the hypothesis that free radical generation may be providing one of the driving forces behind nigral cell degeneration in the disease. On the other hand, a negative result will be less useful, as one could argue that the wrong antioxidant was chosen or the doses were inadequate. In any case, there is a reasonable chance that this hypothesis may be adequately tested and answers could be forthcoming within the next few years.
MPTP
Laboratory research with the neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) has suggested a different explanation that might explain the sequence of events that lead to Parkinson's disease. It was first observed in 1985 that the effects of MPTP are more pronounced when the compound is given to older animals.'2 3 For example, in our studies, we saw little evidence of neuronal degeneration in young mice given MPTP, but pronounced evidence ofcell death in older animals. '4 This age dependency has been reported by other investigators as well,'5 and raises the possibility of an entirely different sequence of events leading to Parkinson's disease. If the disease is indeed due to an environmental toxin, one could propose that constant exposure early in life would induce little in the way of neuronal degeneration. However, once the nervous system became increasingly susceptible to such a toxin by virtue of the aging process, its neurodegenerative effects might become manifest. This hypothesis still does not explain, however, why some individuals get the disease and others do not, unless it is simply a matter of who gets exposed to the causative agent and who does not. The issue remains a critical one in regard to the environmental hypothesis; for the answer, we may have to turn to our colleagues in the field of epidemiology.
MPTP has also given us cause to consider another phenomenon. It is now well known that MPTP is 15 probably a protoxin, requiring conversion by MAO B to MPP +, the putative toxic metabolite of this compound. While most substances in the brain decline with normal aging, MAO B (but not A) has been shown, both in rodents'6 and primates,'7 including the human,'8 to increase with aging. The mechanism of this increase is not understood, but it could provide a means whereby increasing amounts of a neurotoxin are generated from environmental exposure to a protoxin. Once again, the DATATOP study may provide help in answering this question, since the other drug to be tested is the selective MAO B inhibitor deprenyl. As a result of the DATATOP study, as well as a similar study that we are in the process of concluding,'9 we should soon learn if blocking MAO B on a chronic basis will favourably alter the course of Parkinson's disease.
How chronic exposure to an MPTP-like toxin might occur is unclear, but one interesting possibility relates to the adrenal gland. In our studies in primates given MPTP, the adrenal gland contained approximately ten-fold as much MPP + as in any area of the body or brain; further, MPP + persists in the gland for a prolonged period of time. Similar results have been obtained by Johannessen and colleagues.' It has now been shown that MPP+ is stored in the chromaffin granules within the adrenal medulla.2' Is it possible that the adrenal gland might act as a sequestering pocket? If so, it could provide a source for the slow release of neurotoxin into the body and, perhaps, eventually the brain. As the list of toxic MPTP analogues continues to grow, it seems reasonable to suggest that this family of catecholaminergic toxins warrants close study. It will, of course, be of great interest to see if one or more of them are ever discovered to exist either in the man-made or natural environment.
Lessons from Guam
Currently, there is great interest in the aetiology of the amyotrophic lateral sclerosis-Parkinsonism-dementia (ALS/PD) complex of Guam. The data that support this hypothesis are the result of work with agonist-sensitive adenylate cyclase. It has been known for some time that this system can be down-regulated by chronic exposure to alcohol. Recently, it has been shown by Tabakoff and colleagues,26 using human platelets, that this downregulation can persist for a number of years after alcohol exposure (it is not yet absolutely certain that this down-regulation preceded the alcoholism, however). More recently, evidence has been reported indicating that this alteration is secondary to downregulation of messenger RNA synthesis.27 The important concept here is that it is apparently possible to alter selectively the cell's ability to produce messenger RNA, and that this alteration can last for years.
Applying this concept to Parkinson's disease, one could postulate that exposure to a neurotoxicant might permanently alter the neuron's own genetic machinery. This in turn might result in the inability to synthesise a critical enzyme in adequate amounts, eventually leading to the cell's demise. Of course these ideas are only speculative, but they may represent a future area of research, should our current efforts to explore the evolution of events leading to Parkinson's disease fail to bear fruit.
